Avalon GloboCare Corp. is a clinical-stage, vertically integrated, CellTech bio-developer. The Company provides immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics, and therapeutics. It operates through two segments: real property and medical related consulting services. Its major clinical programs include AVA-001, AVA-011 and FLASH-CAR, ACTEX, and AVA-Trap. It also provides strategic advisory and outsourcing services to facilitate and enhance its client's growth and development, as well as competitiveness in healthcare and CellTech industry markets. Its downstream medical team and facility consists of affiliated hospital networks and experts specialized in hematology, oncology, cellular immunotherapy, hematopoietic stem/progenitor cell transplant, as well as regenerative therapeutics. Its services include research studies, executive education, daily online executive briefings, expert advisory services, and consulting and management services.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)